Mar. 19 at 5:57 PM
$PDSB On watch! Not ready to load. But dang it is promising..
Why? 👇
The Regulatory "Wildcard"
Because PDS0101 has FDA Fast Track designation, they have two secret weapons:
One, they can submit finished sections of their BLA (Biologics License Application) as they complete them, rather than waiting for the entire package.
Priority Review: This shrinks the FDA’s review window from 10 months down to 6 months.
So while the path to accelerated approval is clear, the company's financial "runway" is the secondary clock.
👇
The Cash Burn: As of early 2026, the company has been burning roughly
$32 million annually.
The Funding Gap: They will likely need another capital injection or a major partnership to reach that 2027 finish line.
Remember, they need to be above
$1 in August...🤔
